ARTICLE | Management Tracks
Vertex’s Hughes moves to Teva
Plus new CCO at Fate and updates from Nektar, Clover, ReviR and CARB-X
July 1, 2022 8:30 PM UTC
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Eric Hughes as EVP, global R&D and CMO. Hughes, who will be based in Teva’s U.S. headquarters in Parsippany, N.J., was SVP of clinical development and translational medicine at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), and head of the immunology, hepatology and dermatology global development unit at Novartis AG (SIX:NOVN; NYSE:NVS).
Stem cell therapy company Fate Therapeutics Inc. (NASDAQ:FATE) hired Brian Powl as CCO. Powl joins Fate from MEI Pharma Inc. (NASDAQ:MEIP) where he was SVP, commercial development and marketing. Prior to that, he was VP, global commercial CAR T lead at Celgene Corp...